A client receiving belzutifan develops worsening fatigue and dyspnea. Review the record and select the priority action.
Chart/Exhibit
Choose your responses, then check the answer.
Explanation
Belzutifan can cause severe anemia and hypoxia. Hemoglobin 7.6 g/dL with oxygen saturation 86% at rest requires withholding therapy and urgent assessment, oxygen support, and severity-directed oncology management.
Quick answer Escalate severe anemia plus resting hypoxia during belzutifan therapy.
Why this is correct HIF-2 alpha inhibition can reduce erythropoietin signaling and contribute to anemia. The label also requires baseline and serial oxygen monitoring and interruption for clinically important resting hypoxia.
Easy analogy or mental picture Build a medication-safety chain: identify the changing cue, connect it to the labeled toxicity or interaction, interrupt preventable exposure, stabilize the client, and verify a measurable response.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, or delay escalation leave the client at risk.
References
1DailyMed: WELIREG (belzutifan)Anemia and hypoxia monitoring, dose interruption thresholds, urgent oxygen support, and life-threatening toxicity response
Oncology medication-safety reviewVerify indication, current assessment, laboratory and oxygen trends, interactions, urgent toxicity cues, authorized action, and measurable follow-up.